205 related articles for article (PubMed ID: 31120905)
1. Foramen magnum stenosis and midface hypoplasia in C-type natriuretic peptide-deficient rats and restoration by the administration of human C-type natriuretic peptide with 53 amino acids.
Yotsumoto T; Morozumi N; Furuya M; Fujii T; Hirota K; Ueda Y; Nakao K; Yamanaka S; Yoshikiyo K; Yoshida S; Nishimura T; Abe Y; Jindo T; Ogasawara H; Yasoda A
PLoS One; 2019; 14(5):e0216340. PubMed ID: 31120905
[TBL] [Abstract][Full Text] [Related]
2. Circulatory CNP Rescues Craniofacial Hypoplasia in Achondroplasia.
Yamanaka S; Nakao K; Koyama N; Isobe Y; Ueda Y; Kanai Y; Kondo E; Fujii T; Miura M; Yasoda A; Nakao K; Bessho K
J Dent Res; 2017 Dec; 96(13):1526-1534. PubMed ID: 28644737
[TBL] [Abstract][Full Text] [Related]
3. Exogenous C-type natriuretic peptide restores normal growth and prevents early growth plate closure in its deficient rats.
Hirota K; Furuya M; Morozumi N; Yoshikiyo K; Yotsumoto T; Jindo T; Nakamura R; Murakami K; Ueda Y; Hanada T; Sade H; Yoshida S; Enomoto K; Kanai Y; Yamauchi I; Yamashita T; Ueda-Sakane Y; Fujii T; Yasoda A; Inagaki N
PLoS One; 2018; 13(9):e0204172. PubMed ID: 30235256
[TBL] [Abstract][Full Text] [Related]
4. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H
J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
[TBL] [Abstract][Full Text] [Related]
5. Circulatory C-type natriuretic peptide reduces mucopolysaccharidosis-associated craniofacial hypoplasia in vivo.
Kashiwagi M; Nakao K; Yamanaka S; Yamauchi I; Yamashita T; Fujii T; Ueda Y; Kawai MY; Watanabe T; Fukuhara S; Bessho K
PLoS One; 2022; 17(11):e0277140. PubMed ID: 36355797
[TBL] [Abstract][Full Text] [Related]
6. Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death.
Fujii T; Hirota K; Yasoda A; Takizawa A; Morozumi N; Nakamura R; Yotsumoto T; Kondo E; Yamashita Y; Sakane Y; Kanai Y; Ueda Y; Yamauchi I; Yamanaka S; Nakao K; Kuwahara K; Jindo T; Furuya M; Mashimo T; Inagaki N; Serikawa T; Nakao K
PLoS One; 2018; 13(3):e0194812. PubMed ID: 29566041
[TBL] [Abstract][Full Text] [Related]
7. Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice.
Kake T; Kitamura H; Adachi Y; Yoshioka T; Watanabe T; Matsushita H; Fujii T; Kondo E; Tachibe T; Kawase Y; Jishage K; Yasoda A; Mukoyama M; Nakao K
Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1339-48. PubMed ID: 19808910
[TBL] [Abstract][Full Text] [Related]
8. [Genetic basis for skeletal disease. CNP therapy for achondroplasia].
Yasoda A; Nakao K
Clin Calcium; 2010 Aug; 20(8):1212-8. PubMed ID: 20675932
[TBL] [Abstract][Full Text] [Related]
9. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.
Breinholt VM; Rasmussen CE; Mygind PH; Kjelgaard-Hansen M; Faltinger F; Bernhard A; Zettler J; Hersel U
J Pharmacol Exp Ther; 2019 Sep; 370(3):459-471. PubMed ID: 31235532
[TBL] [Abstract][Full Text] [Related]
10. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.
Wendt DJ; Dvorak-Ewell M; Bullens S; Lorget F; Bell SM; Peng J; Castillo S; Aoyagi-Scharber M; O'Neill CA; Krejci P; Wilcox WR; Rimoin DL; Bunting S
J Pharmacol Exp Ther; 2015 Apr; 353(1):132-49. PubMed ID: 25650377
[TBL] [Abstract][Full Text] [Related]
11. The effects of C-type natriuretic peptide on craniofacial skeletogenesis.
Nakao K; Okubo Y; Yasoda A; Koyama N; Osawa K; Isobe Y; Kondo E; Fujii T; Miura M; Nakao K; Bessho K
J Dent Res; 2013 Jan; 92(1):58-64. PubMed ID: 23114031
[TBL] [Abstract][Full Text] [Related]
12. Is there a correlation between sleep disordered breathing and foramen magnum stenosis in children with achondroplasia?
White KK; Parnell SE; Kifle Y; Blackledge M; Bompadre V
Am J Med Genet A; 2016 Jan; 170A(1):32-41. PubMed ID: 26394798
[TBL] [Abstract][Full Text] [Related]
13. Best practices in the evaluation and treatment of foramen magnum stenosis in achondroplasia during infancy.
White KK; Bompadre V; Goldberg MJ; Bober MB; Campbell JW; Cho TJ; Hoover-Fong J; Mackenzie W; Parnell SE; Raggio C; Rapoport DM; Spencer SA; Savarirayan R
Am J Med Genet A; 2016 Jan; 170A(1):42-51. PubMed ID: 26394886
[TBL] [Abstract][Full Text] [Related]
14. C-type natriuretic peptide restores impaired skeletal growth in a murine model of glucocorticoid-induced growth retardation.
Ueda Y; Yasoda A; Yamashita Y; Kanai Y; Hirota K; Yamauchi I; Kondo E; Sakane Y; Yamanaka S; Nakao K; Fujii T; Inagaki N
Bone; 2016 Nov; 92():157-167. PubMed ID: 27594049
[TBL] [Abstract][Full Text] [Related]
15. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery.
Savarirayan R; Irving M; Maixner W; Thompson D; Offiah AC; Connolly DJ; Raghavan A; Powell J; Kronhardt M; Jeha G; Ghani S; Fisheleva E; Day JR
Sci Prog; 2021; 104(1):368504211003782. PubMed ID: 33761804
[TBL] [Abstract][Full Text] [Related]
16. Achondroplasia in children: correlation of ventriculomegaly, size of foramen magnum and jugular foramina, and emissary vein enlargement.
Bosemani T; Orman G; Hergan B; Carson KA; Huisman TA; Poretti A
Childs Nerv Syst; 2015 Jan; 31(1):129-33. PubMed ID: 25249421
[TBL] [Abstract][Full Text] [Related]
17. Improvement in ventriculomegaly following cervicomedullary decompressive surgery in children with achondroplasia and foramen magnum stenosis.
Kashanian A; Chan J; Mukherjee D; Pressman BD; Krakow D; Danielpour M
Am J Med Genet A; 2020 Aug; 182(8):1896-1905. PubMed ID: 32525257
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
[TBL] [Abstract][Full Text] [Related]
19. Effect of C-type natriuretic peptide on craniofacial skeletogenesis in mice during the pubertal growth spurt.
Kashiwagi M; Nakao K; Yamanaka S; Yamauchi I; Yamashita T; Fujii T; Ueda Y; Kawai MY; Watanabe T; Fukuhara S; Bessho K
Arch Oral Biol; 2022 Jul; 139():105433. PubMed ID: 35525017
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias.
Yasoda A; Kitamura H; Fujii T; Kondo E; Murao N; Miura M; Kanamoto N; Komatsu Y; Arai H; Nakao K
Endocrinology; 2009 Jul; 150(7):3138-44. PubMed ID: 19282381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
